Initiatives for Sustainable Growth
Terumo Corporation
President and Representative Director
Yutaro Shintaku
May. 8, 2015
1/9

Update on The “Roadmap to FY16”
Secure a foothold in FY13-14⇒Transformed product portfolio of Hospital and*1OPM Target in FY16

20%

Laboratory Business in Europe

17.5%

Closed the factory for blood bags inAchieve FY14 guidance

17.4%
17.0%

Changchun, China

20.0%

Actual17.3%

Guidance

15%⇒Achieved record-high operating income thanks
to the sales and profit growth in Cardiac & VascularTarget OPM 20% by FY16
⇒Profitability improvement of Blood Management

10%*1 Excl. amortization of goodwill and intangibles
with related to the acquisition of CaridianBCT

FY13

FY14

FY15
FY16Guidance Targetand General Hospital holds a key.

© Terumo Corporation

2015/5/8

2/9

Proactively Addressing Environmental Changes
Respond to environmental changes in corporate governance•Transition to “a Company with an Audit/Supervisory Committee”
based on the Act for the Partial Amendment of the Companies Act•

Comply with the Corporate Governance Code⇒Both initiatives aiming for enhancing growth-oriented governanceStrengthen global management infrastructure•

Introduce 6 CXO positions. Business-led management andCXO structure are the two wheels of a cart.

Overcome foreign exchange fluctuations•

Optimize product portfolio and production footprint© Terumo Corporation

2015/5/8

3/9

Highlights of Cardiac & Vascular Company
Expand business of Interventional Oncology (Cancer treatment)•

Double-digit growth expected•

Terumo’s unique competitiveness can be leveraged in this field.
Expand business based on transcatheter arterial chemoembolization withdrug-chargeable embolic particles (beads) developed in-house received
CE mark approval.

Femoral approach in most cases ⇒ Promote TRILaunch Ultimaster in Japan and further gain market share
Neurovascular: continue to expand sales of non-coil new products© Terumo Corporation

2015/5/8

4/9

Launch Ultimaster in Japan and Further Gain Market ShareOur DES market share is expected to surpass the record-high 10%.
Thousandunits•Great system maneuverability andlesion accessibility•Applicable to complex lesions•Broader size variation

300

200

15%

10%

Ultimaster (sales units)
Nobori (sales units)
DES share (excl. U.S.)

1005%00%
FY08

FY09

FY10

FY11

FY12FY13FY14© Terumo Corporation

FY15
2015/5/8

FY16
5/9

Neurovascular：Continue to Expand Sales of Non-coil New Products
Billion yen<% share of sales>
Clotretriever
Flowdiverter

Non-coil49%

Occlusion
balloon

20%
Coil
51%

Coil80%© Terumo Corporation

2015/5/8

6/9

Highlights of General Hospital Company
Improve profitability of I.V. solutions throughproduction technology innovation
Self-monitoring blood glucose meter:
Aim for top market share in Japan
Innovation history of “Needle and Syringe”• Prefilled syringes (1999-): Improved safety• Nanopass (2005-): Improved patients QOLDermis• Intradermal injection device (2015*)
Injection device that does not look like
injection device

About2 mm

Accurate injection directly to the dermis where
many immune cells exist*Filed an application for the manufacture and sales approval in Japan© Terumo Corporation

2015/5/8

7/9

Highlights of Blood Management Company■Improve operational efficiency and reduce manufacturing costs
to deal with price erosion• The new factory, Terumo BCT Vietnam, is scheduled to begin its
operation in Q3 FY2015■Accelerate growth of high-margin products (CAGR for last 3 years: 10%)• Therapeutic apheresis
Expand indications• Contribute to cell-based
immunotherapy
Cancer immunotherapy

Therapeutic apheresissystem© Terumo Corporation

Cell expansion system
2015/5/8

8/9

IR Contact
Terumo Corporation
Corporate Communication (IR) Dept.
E-mail: kouhou_terumo01@terumo.co.jp

Among the information that Terumo discloses, the forward-looking statements including
financial projections are based upon our assumptions using information available to us at thetime and are not intended to be guarantees of future events or performance. Accordingly, it
should be noted that actual results may differ from those forecasts on projections due tovarious factors. Factors affecting to actual results include, but are not limited to, changes in
economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state ofcompetition.
The market share information in this presentation is partly derived from our own independentresearch.

© Terumo Corporation

2015/5/8

9/9